Download PDF
Planta Med 2010; 76(11): 1094-1102
DOI: 10.1055/s-0030-1249898
Cancer Therapy
Reviews
© Georg Thieme Verlag KG Stuttgart · New York

Metabolomics: A Tool for Anticancer Lead-Finding from Natural Products

Hye Kyong Kim1 , Erica G. Wilson1 , Young Hae Choi1 , Robert Verpoorte1
  • 1Section Metabolomics, Institute of Biology, Leiden University, Leiden, Netherlands
Further Information

Publication History

received March 3, 2010 revised April 6, 2010

accepted April 9, 2010

Publication Date:
19 May 2010 (online)

   Permissions and Reprints

Abstract

Natural products have been the source of many drugs used in modern therapeutics, and particularly in the case of anticancer drugs, more than 50 % originally came from natural products. Their importance as a source of leads for new drugs therefore cannot be underestimated. However, due to the painstaking way of conventional lead-finding, the attention towards natural products has been deviated in the last decades. A new strategy for the detection of active compounds is necessary to get natural product research out of its stalemate. Metabolomics, with its holistic approach and the possibility it provides for the simultaneous detection of all sorts of metabolites, has the potential to be instrumental for this new approach. Therefore, this review aims at providing examples that illustrate the possibilities of using metabolomics as a tool to find active compounds from natural products, specifically anticancer drugs. Two different methods, in silico and in situ, have been introduced as possible approaches. Current methods to detect anticancer activity in natural products have been briefly reviewed and compared in the first section, and various applications of metabolomics in cancer research are mentioned as they can provide comprehensive information of cancer metabolites utilized in the in situ approach. Metabolomics will certainly improve the efficiency of lead-finding from natural products and thus reinstate this prolific source of potential anticancer drugs.

Key words

natural product - anticancer - metabolomics - new approach - in silico - in situ

References

  • 1 Newman D J, Cragg G M. Natural products as sources of new drugs over the last 25 years.  J Nat Prod. 2007;  70 461-477
    CrossrefPubMedGoogle Scholar
  • 2 Verpoorte R, Choi Y H, Kim H K. Ethnopharmacology and systems biology: a perfect holistic match.  J Ethnopharmacol. 2005;  100 53-56
    CrossrefPubMedGoogle Scholar
  • 3 Ulrich-Merzenich G, Zeitler H, Jobst D, Panek D, Vetter H, Wagner H. Application of the ‘‘-omic- technologies in phytomedicine.  Phytomedicine. 2007;  14 70-82
    CrossrefPubMedGoogle Scholar
  • 4 Rochfort S. Metabolomics reviewed: a new “omic” platform technology for systems biology and implications for natural products research.  J Nat Prod. 2005;  68 1813-1820
    CrossrefPubMedGoogle Scholar
  • 5 Craige Trenerry V, Rochfort S J. Natural products research and metabolomics. Mander L, Liu H – W Comprehensive natural products II: chemistry and biology. Amsterdam; Elsevier 2010: 595-628
    PubMedGoogle Scholar
  • 6 Roos G, Röseler C, Berger-Bűter K, Simmen U. Classification and correction of St. John's wort extracts by nuclear magnetic resonance spectroscopy, multivariate data analysis and pharmacological activity.  Planta Med. 2004;  70 771-777
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Kim H K, Choi Y H, Erkelens C, Lefeber A W M, Verpoorte R. Metabolic fingerprinting of Ephedra species using 1H-NMR spectroscopy and principal component analysis.  Chem Pharm Bull. 2005;  53 105-109
    CrossrefPubMedGoogle Scholar
  • 8 Yang S Y, Kim H K, Lefeber A W M, Erkelens C, Angelova N, Choi Y H, Verpoorte R. Application of two-dimensional nuclear magnetic resonance spectroscopy to quality control of ginseng commercial products.  Planta Med. 2006;  72 364-369
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Choi Y H, Tapias E C, Kim H K, Lefeber A W M, Erkelens C, Verhoeven J T J, Brzin J, Zel J, Verpoorte R. Metabolic discrimination of Catharanthus roseus leaves infected by phytoplasma using 1H-NMR spectroscopy and multivariate data analysis.  Plant Physiol. 2004;  135 2398-2410
    CrossrefPubMedGoogle Scholar
  • 10 Liang Y-S, Choi Y H, Kim H K, Linthorst H J M, Verpoorte R. Metabolomic analysis of methyl jasmonate treated Brassica rapa leaves by two dimensional NMR spectroscopy and multivariate analysis.  Phytochemistry. 2006;  67 2503-2511
    CrossrefPubMedGoogle Scholar
  • 11 Leiss K A, Choi Y H, Abdel-Farid I B, Verpoorte R, Klinkhamer P G L. NMR metabolomics of thrips (Frankliniella occidentalis) resistance in Senecio hybrids.  J Chem Ecol. 2009;  35 219-229
    CrossrefPubMedGoogle Scholar
  • 12 Choi H K, Choi Y H, Verberne M, Lefeber A W M, Erkelens C, Verpoorte R. Metabolic fingerprinting of wild type and transgenic tobacco plants by 1H NMR and multivariate analysis technique.  Phytochemistry. 2004;  65 857-864
    CrossrefPubMedGoogle Scholar
  • 13 Le Gall G, Metzdorff S B, Pedersen J, Bennett R N, Colquhoun I J. Metabolite profiling of Arabidopsis thaliana (L.) plants transformed with an antisense chalcone synthase gene.  Metabolomics. 2005;  1 181-198
    CrossrefPubMedGoogle Scholar
  • 14 Sumner L W, Mendes P, Dixon R A. Plant metabolomics: large-scale phytochemistry in the functional genomics era.  Phytochemistry. 2003;  62 817-836
    CrossrefPubMedGoogle Scholar
  • 15 Nicholson J K, Lindon J C, Holmes E. ‘Metabonomics : understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data.  Xenobiotica. 1999;  29 1181-1189
    CrossrefPubMedGoogle Scholar
  • 16 Nicholson J K, Lindon J C. Systems biology – metabonomics.  Nature. 2008;  455 1054-1056
    CrossrefPubMedGoogle Scholar
  • 17 Verpoorte R, Choi Y H, Mustafa N R, Kim H K. Metabolomics: back to basics.  Phytochem Rev. 2008;  7 525-537
    CrossrefPubMedGoogle Scholar
  • 18 Beckonert O, Keun H C, Ebbels T M D, Bundy J, Holmes E, Lindon J C, Nicholson J K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts.  Nat Protoc. 2007;  2 2692-2703
    CrossrefPubMedGoogle Scholar
  • 19 Broberg A, Kenne L. Use of high-resolution magic angle spinning nuclear magnetic resonance spectroscopy for in situ studies of low-molecular-mass compounds in red algae.  Anal Biochem. 2000;  284 367-374
    CrossrefPubMedGoogle Scholar
  • 20 Suggitt M, Bibby M C. 50 years of preclinical anticancer drug screening: Empirical to target-driven approaches.  Clin Cancer Res. 2005;  11 971-981
    PubMedGoogle Scholar
  • 21 Gibbs J B. Mechanism-based target identification and drug discovery in cancer research.  Science. 2000;  287 1969-1972
    CrossrefPubMedGoogle Scholar
  • 22 Damia G, D'Incalci M. Contemporary pre-clinical development of anticancer agents – what are the optimal preclinical models?.  Eur J Cancer. 2009;  45 2768-2781
    CrossrefPubMedGoogle Scholar
  • 23 Holbeck S L. Update on NCI in vitro drug screen utilities.  Eur J Cancer. 2004;  40 785-793
    CrossrefPubMedGoogle Scholar
  • 24 Kinghorn A D, Farnsworth N R, Soejarto D D, Cordell G A, Swanson S M, Pezzuto J M, Wani M C, Wall M E, Oberlies N H, Kroll D J, Kramer R A, Rose W C, Vite G D, Fairchild C R, Peterson R W, Wild R. Novel strategies for the discovery of plant-derived anticancer agents.  Pharm Biol. 2003;  41 53-67
    CrossrefPubMedGoogle Scholar
  • 25 Lin R Z, Chang H Y. Recent advances in three-dimensional multicellular spheroid culture for biomedical research.  Biotechnol J. 2008;  3 1172-1184
    CrossrefPubMedGoogle Scholar
  • 26 Kinghorn A D, Farnsworth N R, Beecher C W W, Soejarto D D, Cordell G A, Pezzuto J M, Wall M E, Wani M C, Brown D M, O'Neill M J, Lewis J A, Besterman J M. Novel strategies for plant-derived anticancer agents.  Int J Pharmacognosy. 1995;  33 48-58
    CrossrefPubMedGoogle Scholar
  • 27 Kinghorn A D, Farnsworth N R, Soejarto D D, Cordell G A, Pezzuto J M, Udeani G O, Wani M C, Wall M E, Navarro H A, Kramer R A, Menendez A T, Fairchild C R, Lane K E, Forenza S, Vyas D M, Lam K S, Shu Y-S. Novel strategies for the discovery of plant-derived anticancer agents.  Pure Appl Chem. 1999;  71 1611-1618
    CrossrefPubMedGoogle Scholar
  • 28 Kinghorn A D, Farnsworth N R, Soejarto D D, Cordell G A, Swanson S M, Pezzuto J M, Wani M C, Wall M E, Oberlies N H, Kroll D J, Kramer R A, Rose W C, Vite G D, Fairchild C R, Peterson R W, Wild R. Novel strategies for the discovery of plant-derived anticancer agents.  Pharm Biol. 2003;  41 53-67
    CrossrefPubMedGoogle Scholar
  • 29 Kinghorn A D, Su B N, Jang D S, Chang L C, Lee D, Gu J Q, Carcache-Blanco E J, Pawlus A D, Lee S K, Park E J, Cuendet M, Gills J J, Bhat K, Park H S, Mata-Greenwood E, Song L L, Jang M, Pezzuto J M. Natural inhibitors of carcinogenesis.  Planta Med. 2004;  70 691-705
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Balunas M J, Kinghorn A D. Drug discovery from medicinal plants.  Life Sci. 2005;  78 431-441
    CrossrefPubMedGoogle Scholar
  • 31 Boros L G, Brackett D J, Harrigan G G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP).  Curr Cancer Drug Targets. 2003;  3 445-453
    CrossrefPubMedGoogle Scholar
  • 32 Brindle J T, Antti H, Holmes E, Tranter G, Nicholson J K, Bethell H W L, Clarkec S, Schofield P M, McKilligin E, Mosedale D E, Grainger D J. Rapid and non-invasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics.  Nat Med. 2002;  8 1439-1444
    CrossrefPubMedGoogle Scholar
  • 33 Lindskog M, Spenger C, Jarvet J, Gräslund A, Kogner P. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.  J Natl Cancer Inst. 2004;  96 1457-1466
    PubMedGoogle Scholar
  • 34 Robertson D G. Metabonomics in toxicology: a review.  Toxicol Sci. 2005;  85 809-822
    CrossrefPubMedGoogle Scholar
  • 35 Leo A D, Claudino W, Colangiuli D, Bessi S, Pestrin M, Biganzoli L. New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer.  Ann Oncol. 2007;  18 8-14
    PubMedGoogle Scholar
  • 36 Lindon J C, Holmes E, Nicholson J K. Metabonomics and its role in drug development and disease diagnosis.  Expert Rev Mol Diagn. 2004;  4 189-199
    CrossrefPubMedGoogle Scholar
  • 37 Gribbestad I S, Sitter B, Lundgren S, Krane J, Axelson D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy.  Anticancer Res. 1999;  19 1737-1746
    PubMedGoogle Scholar
  • 38 Sitter B, Lundgren S, Bathen T F, Halgunset J, Fjosne H E, Gribbestadl I S. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.  NMR Biomed. 2006;  19 30-40
    CrossrefPubMedGoogle Scholar
  • 39 Spratlin J L, Serkova N J, Eckhardt S G. Clinical applications of metabolomics in oncology: a review.  Clin Cancer Res. 2009;  15 431-440
    CrossrefPubMedGoogle Scholar
  • 40 Yang C, Richardson A D, Smith J W, Osterman A. Comparative metabolomics of breast cancer.  Pac Symp Biocomput. 2007;  181-192
    PubMedGoogle Scholar
  • 41 Swanson M G, Zektzer A S, Tabatabai Z L, Simko J, Jarso S, Keshari K R, Schmitt L, Carroll P R, Shinohara K, Vigneron D B, Kurhanewicz J. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.  Magn Reson Med. 2006;  55 1257-1264
    CrossrefPubMedGoogle Scholar
  • 42 Yang J, Xu G, Zheng Y, Kong H, Pang T, Lva S, Yang Q. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases.  J Chromatogr B. 2004;  813 59-65
    CrossrefPubMedGoogle Scholar
  • 43 Griffin J L, Shockcor J P. Metabolic profiles of cancer cells.  Nat Rev Cancer. 2004;  4 551-561
    CrossrefPubMedGoogle Scholar
  • 44 Odunsi K, Wollman R M, Ambrosone C B, Hutson A, McCann S E, Tammela J, Geisler J P, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer J L. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.  Int J Cancer. 2005;  113 782-788
    CrossrefPubMedGoogle Scholar
  • 45 Robertson D G, Reily M D, Sigler R E, Wells D F, Paterson D A, Braden T K. Metabonomics: Evaluation of nuclear magnetic resonance and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants.  Toxicol Sci. 2000;  57 326-337
    CrossrefPubMedGoogle Scholar
  • 46 Claudino W M, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications.  J Clin Oncol. 2007;  25 2840-2846
    CrossrefPubMedGoogle Scholar
  • 47 Morse D L, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, Howison C, Gillies R J. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized 31P MRS of human breast cancer xenografts and in vitro by high-resolution 31P NMR spectroscopy of cell extracts.  Magn Reson Med. 2007;  58 270-280
    CrossrefPubMedGoogle Scholar
  • 48 Negendank W G. Studies of human tumors by MRS: a review.  NMR Biomed. 1992;  5 303-324
    CrossrefPubMedGoogle Scholar
  • 49 Sterin M, Cohen J S, Mardor Y, Berman E, Ringel I. Levels of phospholipids metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magetic resonance spectroscopy study.  Cancer Res. 2001;  61 7536-7543
    PubMedGoogle Scholar
  • 50 Chung Y L, Griffiths J R. Using metabolomics to monitor anticancer drugs. Kroemer G, Mumberg D, Keun K, Riefke B, Steger-Hartmann T, Petersen K Oncogenes meet metabolism. Ernst Schering Foundation Symposium Procedings. Heidelberg; Springer-Verlag 2008: 55-78
    PubMedGoogle Scholar
  • 51 Dixon R A, Sumner L W. Legume natural producs: understanding and manipulating complex pathways for human and animal health.  Plant Physiol. 2003;  131 878-885
    CrossrefPubMedGoogle Scholar
  • 52 Zhi Biao-Yi, Yan Yu Y, Yi Zeng-Liang. Investigation of antimicrobial model of Hemsleya pengxianensis W.J. Chang and its main active component by metabolomics technique.  J Ethnopharmacol. 2008;  116 89-95
    CrossrefPubMedGoogle Scholar
  • 53 Liu Y, Wen J, Wang Y, Li Y, Xu W. Postulating modes of action of compounds with antimicrobial activities through metabolomics analysis.  Chromatographia. 2010;  71 253-258
    CrossrefPubMedGoogle Scholar
  • 54 Cardoso-Taketa A T, Pereda-Miranda R, Choi Y H, Verpoorte R, Villarreal M L. Metabolic profiling of the Mexican anxiolytic and sedative plant Galphimia glauca using nuclear magnetic resonance spectroscopy and multivariate data analysis.  Planta Med. 2008;  74 1295-1301
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics.  Chemometrics Intell Lab Syst. 2001;  58 109-130
    CrossrefPubMedGoogle Scholar
  • 56 Holmes E, Antti H. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterizing and interpreting complex biological NMR spectra.  Analyst. 2002;  127 1549-1557
    CrossrefPubMedGoogle Scholar
  • 57 Trygg J, Wold S. O2-PLS, a two-block (X–Y) latent variable regression (LVR) method with an integrated OSC filter.  J Chemom. 2003;  17 53-64
    CrossrefPubMedGoogle Scholar
  • 58 Rantalainen M, Cloarec O, Beckonert O, Wilson I D, Jackson D, Tonge R, Rowlinson R, Rayner S, Nickson J, Wilkinson R W, Mills J D, Trygg J, Nicholson J K, Holmes E. Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice.  J Proteom Res. 2006;  5 2642-2655
    CrossrefPubMedGoogle Scholar
  • 59 Ebbels T M D, Rachel Cavill R. Bioinformatic methods in NMR-based metabolic profiling.  Prog Nucl Magn Reson Spectr. 2009;  55 361-374
    CrossrefPubMedGoogle Scholar
  • 60 Dunn W B. Current trends and future requirements for the mass spectrometric investigation of microbial, mammalian and plant metabolomes.  Phys Biol. 2008;  5 1-24
    PubMedGoogle Scholar
  • 61 Kell D B, Brown M, Hazel M, Davey H M, Dunn W B, Spasic I, Oliver S G. Metabolic footprinting and systems biology: the medium is the message.  Nat Rev Microbiol. 2005;  3 557-565
    CrossrefPubMedGoogle Scholar
  • 62 Allen J, Davey H M, Broadhurst D, Rowland J J, Oliver S G, Kell D B. Discrimination of modes of action of antifungal substances by use of metabolic footprinting.  Appl Environ Microbiol. 2004;  70 6157-6165
    CrossrefPubMedGoogle Scholar
  • 63 Verhoeckx K C M, Bijlsma S, Jespersen S, Ramaker R, Verheij E R, Witkamp R F, van der Greef J, Rodenburg R J T. Characterization of anti-inflammatory compounds using transcriptomics, proteomics, and metabolomics in combination with multivariate data analysis.  Int Immunopharmacol. 2004;  4 1499-1514
    CrossrefPubMedGoogle Scholar
  • 64 Xi Y, De Ropp J S, Viant M R, Woodruff D L, Yu P. Improved identification of metabolites in complex mixtures using HSQC NMR spectroscopy.  Anal Chim Acta. 2008;  614 127-133
    CrossrefPubMedGoogle Scholar
  • 65 Kim H K, Saifullah, Khan S, Wilson E G, Prat Kricun S D, Meissner A, Goraler S, Deelder A M, Choi Y H, Verpoorte R. Metabolic classification of South American Ilex species by NMR-based metabolomics.  Phytochemistry. 2010;  71 773-784
    CrossrefPubMedGoogle Scholar
  • 66 Lewis I A, Schommer S C, Hodis B, Robb K A, Tonelli M, Westler W M, Sussman M R, Markley J L. Method for determining molar concentrations of metabolites in complex solutions from two-dimensional 1H-13C NMR spectra.  Anal Chem. 2007;  79 9385-9390
    CrossrefPubMedGoogle Scholar

Dr. Hye Kyong Kim

Section Metabolomics
Institute of Biology
Leiden University

Einsteinweg 55

P. O. Box 9502

2300RA Leiden

The Netherlands

Phone: + 31 7 15 27 45 10

Fax: + 31 7 15 27 45 11

Email: h.k.kim@chem.leidenuniv.nl

      >